LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.
Leucine rich repeat kinase (LRRK2) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may nonspecifically inhibit LRRK2. Few studies, however, have assessed cancer risk in LRRK2 mutation carriers. To explore this risk, we evaluated records of Ashkenazi Jewish (AJ) PD patients participating in genetic research. Charts were reviewed for 163 unrelated AJ PD patients, 31 of whom harbored the G2019S mutation. History of cancer was queried at baseline intake using a form reviewing medical conditions, and charts were reviewed for all follow-up visits. 9/31 LRRK2 G2019S mutation carriers had nonskin cancers, whereas 15/132 without mutations had nonskin cancers, representing an almost threefold increased risk in this group (HR 2.9, 95% CI 1.3-6.6). Age at first nonskin cancer was younger in the LRRK2 carriers (56.0 years) than the noncarriers (62.0 years), but was not significant. 67% of the LRRK2 carriers had their cancer before the onset of PD, whereas only 40% of noncarriers developed their first nonskin cancer before onset of PD. While further evaluation is warranted, our findings indicate an increased risk of nonskin cancers in LRRK2 G2019S mutation carriers, which may be related to toxic gain of function of mutated LRRK2.
Saunders-Pullman
Rachel
R
Department of Neurology, Beth Israel Medical Center, New York, New York, USA. rsaunder@bethisraelny.org
Barrett
Matthew J
MJ
Stanley
Kaili M
KM
Luciano
Marta San
MS
Shanker
Vicki
V
Severt
Lawrence
L
Hunt
Ann
A
Raymond
Deborah
D
Ozelius
Laurie J
LJ
Bressman
Susan B
SB
D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing; D006801:Humans; D007585:Jews / Q000235:genetics; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009369:Neoplasms / Q000150:complications / Q000235:genetics*; D010300:Parkinson Disease / Q000150:complications / Q000235:genetics*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D012306:Risk; D018709:Statistics, Nonparametric
C495280:LRRK2 protein, human; D000071158:Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; D017346:Protein Serine-Threonine Kinases
Mov Disord. 2007 Jul 15;22(9):1252-7
17534943
Hum Mol Genet. 2007 Sep 1;16(17):2031-9
17584768
J Biol Chem. 2008 Jun 13;283(24):16906-14
18397888
Arch Neurol. 2010 May;67(5):542-7
20457952
Neurology. 2008 Nov 11;71(20):1650; author reply 1650-1
19001259
Neuroscience. 2007 Jul 29;147(4):1047-58
17611037
N Engl J Med. 2006 Jan 26;354(4):424-5
16436782
Nature. 2007 Mar 8;446(7132):153-8
17344846
Cancer Causes Control. 2010 May;21(5):697-707
20054708
Nat Neurosci. 2006 Oct;9(10):1231-3
16980962
Neuron. 2004 Nov 18;44(4):595-600
15541308
J Neurol. 2009 Mar;256(3):483-7
19412725
Biochem J. 2009 Oct 23;424(1):47-60
19740074
Neuron. 2004 Nov 18;44(4):601-7
15541309
Biochem Biophys Res Commun. 2009 Jan 16;378(3):473-7
19027715
Mov Disord. 2010;25 Suppl 1:S40-3
20187256
Ann Neurol. 2006 Feb;59(2):315-22
16437584
Epidemiology. 2006 Sep;17(5):582-7
16837822
Hum Mol Genet. 2006 Jan 15;15(2):223-32
16321986
Hum Mol Genet. 2007 Jun 1;16(11):1319-26
17409193
Cancer Causes Control. 2007 Sep;18(7):705-11
17562193
Biochem Biophys Res Commun. 2009 Nov 20;389(3):449-54
19733152
Ann Neurol. 2002 Mar;51(3):296-301
11891824
Neurology. 2007 Oct 9;69(15):1542-50
17699801
Neurology. 2004 May 11;62(9):1619-22
15136696
Neuroscience. 2008 Mar 18;152(2):429-36
18272292
Biochemistry. 2007 Feb 6;46(5):1380-8
17260967
Biochem J. 2009 Oct 23;424(1):e1-3
19839940
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7
16269541
Exp Cell Res. 2007 Oct 1;313(16):3658-70
17706965
Neurobiol Dis. 2006 Aug;23(2):329-41
16750377
Am J Hum Genet. 2002 Jul;71(1):124-35
12058349
Neurology. 2006 Nov 28;67(10):1786-91
17050822
Neurology. 2009 Oct 20;73(16):1286-91
19841380
Neurology. 2007 Nov 27;69(22):2093-104
17761553
Biochem J. 2007 Jul 15;405(2):307-17
17447891